Abstract
With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Current Pharmaceutical Design
Title: Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Volume: 12 Issue: 14
Author(s): Wesley K. Kroeze and Bryan L. Roth
Affiliation:
Keywords: Obesity-Related Molecular Targets, In Silico Receptoromics, Receptor Databases, GPCR, NC-IUPHAR, Weight Gain
Abstract: With the recently completed sequencing and annotation of the human genome, it has become clear that a significant portion of the genome encodes signal-transducing molecules including receptors, protein kinases, ion channels, transporters and coupling proteins. This review focuses on membrane-localized receptors, which represent the largest single group of signal-transducing molecules. Indeed, one can estimate that nearly 10% of the human genome encodes membrane- localized receptors (e.g. G-protein coupled receptors, ligand-gated ion channels and transporters). We have defined that portion of the human genome that encodes receptors the receptorome. In this article, we will demonstrate how the massively parallel screening of the receptorome provides a facile and under-utilized screening platform for drug discovery. Using case studies, we will show how receptorome-based screening elucidates the mechanisms responsible for serious side-effects of both approved and investigational medications. Additionally, we will provide evidence that receptorome- based screening provides insights into novel therapeutic indications of approved medications and serves to validate targets for therapeutic drug discovery.
Export Options
About this article
Cite this article as:
Kroeze K. Wesley and Roth L. Bryan, Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery, Current Pharmaceutical Design 2006; 12 (14) . https://dx.doi.org/10.2174/138161206776873680
DOI https://dx.doi.org/10.2174/138161206776873680 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Artemisia Species as Potential Weapon Against Agents and Agricultural Pests
Current Biotechnology Preface [Hot Topic: Recent Progress in Cardiovascular Gene Therapy;Emerging to Real Drug? (Guest Editor: Ryuichi Morishita)]
Current Gene Therapy Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatolgy:Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]
Current Pharmaceutical Design Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Analysis of the Selected Biochemical Blood Parameters in Patients After Total Hip Replacement
Current Rheumatology Reviews Vascular Patency: A Biomarker and Clinical Target Quantified with High Resolution MRI and Novel Cellular Pathways
Current Neurovascular Research Beta-Blockers: Effects on Bone Mineral Density and Fracture Risk
Current Rheumatology Reviews Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Fatty Acids and Obesity
Current Pharmaceutical Design Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection
Current HIV Research Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders
Current Medicinal Chemistry Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Roles of Adrenomedullin in Hypertension and Hypertensive Organ Damage
Current Hypertension Reviews The Protective Effects of Extra Virgin Olive Oil on Immune-mediated Inflammatory Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Best Practice for Atrial Fibrillation Patient Education
Current Pharmaceutical Design Introduction: Advancing Drug Discovery for Alzheimers Disease [ ISOA Fifth Annual Investigators Meeting “Recent Advances in Drug Discovery and Development for Alzheimers Disease” Sponsored by Elan Pharmaceuticals Inc, The Graphic Expression, Glaxo Smith Kline Pharmaceuticals, Neurochem Inc, Pfizer Inc. (Guest Editors: Howard M. Fillit and Lorenzo M. Refolo)]
Current Alzheimer Research